What is William Blair’s Forecast for CVRx FY2026 Earnings?

CVRx, Inc. (NASDAQ:CVRX) – Investment analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of CVRx in a report issued on Friday, December 13th. William Blair analyst M. Andrew expects that the company will post earnings of ($1.91) per share for the year. The consensus estimate for CVRx’s current full-year earnings is ($2.62) per share.

Several other equities research analysts also recently weighed in on the stock. Lake Street Capital lifted their price target on shares of CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $14.00 target price on shares of CVRx in a research report on Wednesday, October 23rd. Craig Hallum upped their price target on CVRx from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Piper Sandler reissued an “overweight” rating and issued a $16.00 price objective (up previously from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Finally, Canaccord Genuity Group upped their target price on CVRx from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.67.

CVRx Stock Down 4.3 %

CVRx stock opened at $12.83 on Monday. The company has a market capitalization of $311.31 million, a PE ratio of -4.75 and a beta of 1.20. CVRx has a 12-month low of $6.40 and a 12-month high of $33.13. The firm’s fifty day moving average is $12.60 and its 200 day moving average is $10.45. The company has a quick ratio of 10.23, a current ratio of 11.32 and a debt-to-equity ratio of 0.76.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The business had revenue of $13.37 million during the quarter, compared to analyst estimates of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. During the same period last year, the firm posted ($0.43) earnings per share.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in CVRx in the 3rd quarter valued at $108,000. XTX Topco Ltd bought a new stake in shares of CVRx in the 3rd quarter worth $150,000. Rhumbline Advisers raised its holdings in shares of CVRx by 28.8% in the second quarter. Rhumbline Advisers now owns 17,260 shares of the company’s stock valued at $207,000 after purchasing an additional 3,863 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of CVRx during the second quarter valued at about $218,000. Finally, Jane Street Group LLC boosted its holdings in CVRx by 36.1% during the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after purchasing an additional 5,053 shares during the last quarter. Institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.